by the patient, attempts of intracavitary instillation of an antifungal agent, either through an intrabronchial catheter or percutaneously, have been tried. Systemic antifungal agents are considered to be unvaluable since there is little diffusion of the agent into the cavity containing the fungus ball. Other agents, including sodium iodide, potassium iodide, N-acetylcysteine and aminocaproic acid, have also been used locally, either alone or with antimycotics.
Endocavitary treatment with antifungal agents, including amphotericin B (1-19), nystatin (4, 7), natamycin (20), pimaricin (7), flucytosine (21), miconazole (22) , and ketoconazole (23), was associated with disintegration or a decrease in the size of fungus ball or clinical improvement. To myknowledge, this form of therapy has been employed successfully or with significant improvement in a relatively small number of patients in the English literature. In this issue, Kawamuraet al reported that patients with pulmonary aspergilloma responded poorly to intracavitary injection of amphoterichin B (24).
See also p 209.
Whyattempts of this form of therapy are successful in some patients and unsuccessful in others is not clear. Which antimycotic instilled, the optimal dose and total dosage of the agent and interval of instillation remain to be clarified. The touching time of agent instilled with viable Aspergillus on the surface of the fungus ball may be essential. Moreover, an adjunctive therapy to accelerate destruction of the fungus ball may be favorable. Further study of these problems will be necessary.
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